Search tips
Search criteria 


Logo of emmExperimental and Molecular MedicineArchiveAbout the journalGuide to authors
Exp Mol Med. 2010 May 31; 42(5): 395–405.
Published online 2010 April 5. doi:  10.3858/emm.2010.42.5.041
PMCID: PMC2877254

Chlorpromazine activates p21Waf1/Cip1 gene transcription via early growth response-1 (Egr-1) in C6 glioma cells


2-Chloro-10-[3(-dimethylamino)propyl]phenothiazinemonohydrochloride (chlorpromazine) is a phenothiazine derivative used clinically to control psychotic disorders. It also exhibits an anticancer activity. Treatment with chlorpromazine (CPZ) results in cell-cycle arrest at the G2/M phase in rat C6 glioma cells. CPZ reduces the expression of cell cycle-related proteins, such as cyclin D1, cyclin A, and cyclin B1, but causes an increase in the p21Waf1/Cip1 level. The molecular mechanism by which CPZ regulates p21Waf1/Cip1 expression is unknown. Here, we provide evidence that CPZ activates the p21Waf1/Cip1 gene promoter via induction of the transcription factor early growth response-1 (Egr-1) independently of p53 in C6 cells. A point mutation in the Egr-1-binding motif within the p21Waf1/Cip1 promoter abrogated promoter inducibility due to CPZ. Forced expression of Egr-1 enhanced p21Waf1/Cip1 promoter activity. In contrast, knockdown of endogenous Egr-1 by small interference RNA attenuated CPZ-induced p21Waf1/Cip1 promoter activity. A chromatin immunoprecipitation assay demonstrated that Egr-1 binds to the p21Waf1/Cip1 gene promoter. Further analysis showed that the ERK and JNK MAP kinases are required for induction of Egr-1 by CPZ. Finally, stable silencing of Egr-1 expression lead to attenuated CPZ-inducible p21Waf1/Cip1 expression and inhibited G2/M phase cell-cycle arrest. These results demonstrate that a functional link between ERK and JNK MAP kinase pathways and p21Waf1/Cip1 induction via Egr-1 contributes to CPZ-induced anticancer activity in C6 glioma cells.

Keywords: chlorpromazine, c-Jun N-terminal kinase, cyclin-dependent kinase inhibitor p21, early growth response-1, extracellular signal-regulated kinase, tumor suppressor protein p53


Some cancer patients demonstrate psychological symptoms, such as pain, anxiety, psychosis, and depression with suicidal tendencies (Derogatis et al., 1983). Several psychotropic drugs, such as phenothiazine derivatives including chlorpromazine (CPZ), trifluoperazine (TFP), and perphenazine (PPZ), can be useful for controlling psychiatric symptoms or chemotherapy side effects in advanced cancer patients (Noyes, 1981). The pharmacological mechanism of these derivatives to diminish these symptoms is mainly attributed to their ability to block dopamine receptors (Snyder et al., 1974). However, these drugs possess a wide range of pharmacological actions that may interfere with calmodulin, channel proteins, DNA topoisomerase, oncogenic K-Ras membrane proteins, and other receptors (Zarnowska and Mozrzymas, 2001; Eisenberg et al., 2008). Phenothiazines have been reported to inhibit cell proliferation of various tumor cells (Nordenberg et al., 1999), probably through inhibition of the mitotic kinesin KSP/Eg5 resulting in mitotic arrest (Lee et al., 2007), or inhibition of PDK1/Akt signaling (Choi et al., 2008b).

The cyclin-dependent kinase inhibitor 1A (CDKN1A), also known as p21, Waf1, or Cip1 (p21Waf1/Cip1), is a well-characterized cell-cycle regulator that mainly inhibits the activity of cyclin E/cdk2 (Harper et al., 1993) or the cyclin B/cdk1 complex (Charrier-Savournin et al., 2004) and negatively regulates multiple phases of cell-cycle progression (el-Deiry et al., 1994; Waldman et al., 1996; Chan et al., 2000; Baus et al., 2003). p21Waf1/Cip1 expression was initially identified as a p53-dependent mechanism; however, multiple signals target p21Waf1/Cip1 independently of p53 (Gartel and Tyner, 1999). CPZ exhibits anticancer activities in many types of cancer cells. However, the mechanism of action of CPZ in the regulation of p21Waf1/Cip1 expression remains unknown.

The purpose of this study was to characterize the molecular mechanism of action of CPZ in the regulation of p21Waf1/Cip1 expression in rat C6 glioma cells. Our results showed that CPZ activates p21Waf1/Cip1 promoter activity via Egr-1 independently of p53. In addition, we found that the ERK and JNK MAP kinases are required for CPZ induction of Egr-1 via Ets transcription factor Elk-1. These results provide mechanistic insights into CPZ's antitumor activity and further support for antipsychotic CPZ as a potential therapeutic adjuvant for treatment of glioma.


Effects of CPZ on cell proliferation and cell-cycle progression in C6 glioma cells

To study the mechanism by which CPZ inhibits cell growth, we initially assessed the anti-proliferation efficacy of CPZ using C6 glioma cells. Treatment with CPZ resulted in a concentration- and time-dependent inhibition of cell growth, compared with untreated control cells, reaching a maximum after 24 h with a 20 µM treatment (Figure 1B). At the highest concentration of 40 µM, the level of proliferation was lower than the control levels, probably due to the promotion of cell death. To determine the effect of CPZ on the expression of cell cycle regulatory proteins, Western blot analysis was performed. Time-response analysis showed that the amounts of cyclin D1, cyclin A1, and cyclin B1 were considerably lower after 12 h of CPZ treatment, compared with control cultures (Figure 1C). In contrast, the cycline E level was unchanged. These results suggest that CPZ inhibits proliferation of C6 rat glioma cells, probably due to inhibition of cell-cycle progression through down-regulation of cell cycle regulatory cyclins.

Figure 1
Effects of CPZ on cell proliferation in C6 glioma cells. (A) The chemical structure of CPZ. (B) Cell proliferation assay. C6 cells were seeded into 96-well culture plates and treated with increasing CPZ concentrations for the indicated lengths of time. ...

CPZ activates p21Waf1/Cip1 promoter activity independently of p53

p21Waf1/Cip1 is an important regulator of cell-cycle progression at the G1 (Harper et al., 1993) and G2/M phases (el-Deiry et al., 1994; Gartel and Tyner, 1999; Chan et al., 2000; Baus et al., 2003). Given that accumulation of the p21Waf1/Cip1 protein precedes reduction in other cell cycle regulatory protein levels (Figure 2A), we focused on transcriptional regulation of the p21Waf1/Cip1 gene by CPZ. p53 is a well-known mediator of p21Waf1/Cip1 expression, but a role for p53 in CPZ-induced p21 expression was discounted because (i) the amount of the p53 protein was not changed by CPZ (Figure 2A), (ii) p53-dependent transcriptional activity was not activated by CPZ (Figure 2B), and (iii) CPZ stimulated the promoter activity of the p21-Luc(-150/+38) construct, despite lacking a p53 binding site (Figure 2C). Thus, we suggest that CPZ-induced accumulation of p21Waf1/Cip1 is mediated at the transcriptional level independently of p53 and that the proximal region within -150 bp of the p21Waf1/Cip1 gene promoter is necessary for CPZ-induced activation of p21Waf1/Cip1 expression.

Fig. 2
p53-independent activation of p21Waf1/Cip1 promoter activity by CPZ. (A) C6 cells were treated with 20 µM CPZ for the indicated time periods. Cellular extracts were subjected to Western blot analysis using the indicated antibodies. Each blot represents ...

CPZ activates p21Waf1/Cip1 promoter activity through an Egr-1 response element

Previous studies have demonstrated that Egr-1 transactivates the p21Waf1/Cip1 promoter through a putative Egr-1-response element located between -58 and -51 in the p21Waf1/Cip1 promoter (Ragione et al., 2003; Kim et al., 2007). To evaluate whether an Egr-1-response element between -58 and -51 is involved in mediating CPZ-induced p21Waf1/Cip1 promoter activity, we used the Egr-1 mutant construct p21-Luc(-150/+38)mtEgr-1 (Kim et al., 2007), which disrupted the core sequence of the Egr-1 binding motif (gggg to tttt). Point mutations in the core sequences of the Egr-1 response element resulted in a drastic reduction in CPZ responsiveness (Figure 3A). To further assess the role of Egr-1 in CPZ-induced activation of the p21Waf1/Cip1 promoter, the p21-Luc(-150/+38) reporter lacking the p53-binding site was transfected into C6 cells together with the expression plasmid for Egr-1. p21Waf1/Cip1 promoter activity increased as the amount of transfected Egr-1 increased (Figure 3B), suggesting that Egr-1 mediates p21Waf1/Cip1 transcription in response to CPZ treatment.

Fig. 3
The role of an Egr-1 response element in CPZ-induced activation of p21Waf1/Cip1 promoter activity. (A) Promoter reporter assay. C6 cells were transfected with p21-Luc(-150/+38) (wild type; WT) or the Egr-1 mutant construct (mtEgr1). After 48 h of transfection, ...

To determine binding of Egr-1 to the p21Waf1/Cip1 promoter, we cross-linked the cellular protein with DNA by using formaldehyde after treatment with CPZ. The cross-linked DNA-protein complexes were subjected to chromatin immunoprecipitation (ChIP) using rabbit anti-Egr-1 antibody, and the immunoprecipitated DNA was amplified using PCR with primers targeted to the promoter elements (from -170 to +42) of the p21Waf1/Cip1 gene. The same amount of genomic DNA was used as an input control. After CPZ treatment, we amplified 212-bp fragments of the p21Waf1/Cip1 promoter region using ChIP DNA. Comparison with a non-stimulated control (Figure 3C) indicated that Egr-1 forms a complex with the p21Waf1/Cip1 gene promoter within the chromatin.

To verify the functional role of Egr-1 in CPZ-induced activation of p21Waf1/Cip1 promoter activity, we used an RNA interference approach. The expression plasmid for Egr-1 shRNA (pSilencer/siEgr-1) and the p21-Luc(-150/+38) promoter reporter were co-transfected into C6 cells. The silencing of endogenous Egr-1 significantly attenuated CPZ-induced p21Waf1/Cip1 promoter activity (Figure 3D), suggesting that Egr-1 is required for CPZ activation of p21Waf1/Cip1 transcription. These results suggest that the Egr-1 response element in the proximal region of the p21Waf1/Cip1 gene is necessary for CPZ inducibility in C6 cells.

CPZ up-regulates Egr-1 expression at the transcriptional level

We investigated whether CPZ induces Egr-1 expression in C6 glioma cells. Serum-starved C6 cells were treated with increasing concentrations of CPZ for 2 h, after which the amount of Egr-1 protein was measured using Western blot analysis. CPZ treatment markedly increased Egr-1 protein amounts in a concentration-dependent manner (Figure 4A). A time-course study showed that CPZ increased the abundance of the Egr-1 protein with a peak at 2 h, and maintained the level for up to 4 h (Figure 4B). Northern blot analysis showed that the abundance of Egr-1 mRNA rapidly increased within 30 min after CPZ treatment with a maximum observed at 1 h, whereas the gapdh mRNA level remained constant (Figure 4C).

Fig. 4
Up-regulation of Egr-1 expression by CPZ. (A, B) Western blot analysis. Serum-starved (0.5% serum for 24 h) C6 cells were treated with different concentrations of CPZ for 1 h (A) or 20 µM CPZ for different times (B). Cellular extracts were analyzed ...

CPZ-induced Egr-1 and p21Waf1/Cip1 expressions are mediated by ERK and JNK MAP kinases

Elk-1 is a ternary complex factor (TCF) that forms a complex with the serum response factor (SRF) on the SRE of the Egr-1 gene promoter, and plays a crucial role in transcriptional activation of the Egr-1 gene (Watson et al., 1997; Schratt et al., 2001) Elk-1 is phosphorylated and activated by multiple MAP kinase pathways in response to a variety of extracellular stimuli (Treisman, 1994; Yang et al., 1998; Yang and Sharrocks, 2006). To determine whether CPZ activation of Elk-1 is induced by stimulating MAP kinase signaling, serum-starved C6 cells were treated with CPZ for various time intervals, and then the activation status of the MAP kinase pathway was measured using phospho-specific antibodies. The phosphorylated levels of ERK1/2 and JNK1/2 MAP kinases increased in a time-dependent manner in response to CPZ treatment (Figure 5A). In contrast, the total amount of these proteins did not change, demonstrating an actual increase in their phosphorylation status indicative of increased activity. However, the phosphorylation of p38 MAP kinase decreased below basal levels within 15 min of CPZ treatment. These results suggest that CPZ modulates different MAP kinase pathways.

Fig. 5
Involvement of the ERK and JNK MAP kinase pathways in CPZ-induced p21Waf1/Cip1 expression. (A) C6 cells were serum-starved with 0.5% serum for 24 h, and then treated with 20 µM CPZ for various lengths of time. Western blotting was performed with ...

To assess a possible regulatory relationship between MAP kinase activation and Egr-1 expression due to CPZ, we examined the effect of MAP kinase inhibitors on accumulation of the Egr-1 protein. Pretreatment with the MEK inhibitor U0126 or the JNK inhibitor SP600125, but not with the p38 kinase inhibitor SB203580, blocked the CPZ-induced accumulation of the Egr-1 protein (Figure 5B). Furthermore, treatment with U0126 or SP600125 blocked CPZ-induced p21Waf1/Cip1 promoter activity (Figure 5C) and accumulation of the p21Waf1/Cip1 protein (Figure 5D). These results demonstrate that ERK- and JNK-induced Elk-1 transactivation due to CPZ is functionally linked to induction of p21Waf1/Cip1 expression via Egr-1.

Stable knockdown of Egr-1 expression attenuates CPZ-induced p21Waf1/Cip1 expression

To further corroborate the functional significance of Egr-1 in activation of the p21Waf1/Cip1 gene due to CPZ, we evaluated the effect of stable silencing of endogenous Egr-1 expression on CPZ-induced growth inhibition. Stable knockdown of Egr-1 by RNA interference in C6 cells (C6/siEgr1) was verified using Western blot analysis (Figure 6A). Knock-down of endogenous Egr-1 caused resistance to CPZ-induced inhibition of cell growth, compared with control C6/vec cells (Figure 6B), and prevented CPZ induction of p21Waf1/Cip1 expression (Figure 6C). Furthermore, silencing of Egr-1 expression abrogated CPZ-induced accumulation of G2/M arrest (Figure 6D).

Fig. 6
Effects of stable silencing of endogenous Egr-1 by siRNA on CPZ-induced p21Waf1/Cip1 expression. (A) Knockdown of endogenous Egr-1 expression was verified in stable transfectants of C6 cells expressing Egr-1 siRNA (C6/siEgr1), as compared with control ...


CPZ is a phenothiazine derivative that is widely used as a neuroleptic drug for control of psychotic disorders. In addition to antipsychotic actions, CPZ also displays effective antiproliferative activity in numerous types of cancer cells. In C6 cells, we found that treatment with CPZ resulted in cell-cycle arrest at the G2/M phase with a concomitant decrease in the G1 cell population. In addition, CPZ reduced expression of the cell cycle-related proteins cyclin D1, cyclin A, and cyclin B1, but promoted an accumulation of the p21Waf1/Cip1 protein. p21Waf1/Cip1 is an important regulatory element for cell cycle arrest at the G1 or G2/M phase, and its expression is regulated by diverse external stimuli (Harper et al., 1993; el-Deiry et al., 1994; Waldman et al., 1996; Chan et al., 2000; Baus et al., 2003; Charrier-Savournin et al., 2004). It is well established that p21Waf1/Cip1 transcription is mediated by the tumor suppressor p53 (El-Deiry et al., 1993). However, multiple lines of evidence demonstrate that several transcription factors other than p53, including Egr-1, can bind and activate the p21Waf1/Cip1 promoter (Gartel and Tyner, 1999; Ragione et al., 2003; Kim et al., 2007; Choi et al., 2008a). However, the molecular mechanism by which CPZ up-regulates p21Waf1/Cip1 expression is unknown. This study focused on the regulatory mechanism of p21Waf1/Cip1 induction due to CPZ in C6 cells.

CPZ stimulated p21Waf1/Cip1 promoter activity without significantly affecting the expression and cis-acting activity of p53 in C6 cells. Thus, we assumed that CPZ-induced p21Waf1/Cip1 expression is independent of p53. To test this possibility, we analyzed a response element of the p21Waf1/Cip1 promoter. A luciferase reporter assay was used with a deletion mutant of the p21Waf1/Cip1 promoter construct that lacked a p53 binding site. Results showed that CPZ still induced comparable promoter reporter activity, compared to the full-length p21Waf1/Cip1 promoter construct. This suggested that p53 does not play a central role in CPZ-induced p21Waf1/Cip1 promoter activity. Instead, we found that transcription factor Egr-1 mediates CPZ-induced p21Waf1/Cip1 expression in C6 cells. The putative consensus Egr-1 binding sequence is located in a region from -58 to -51 within the p21Waf1/Cip1 gene (Ragione et al., 2003). By using site-directed mutational analysis of the putative Egr-1-binding sequence within the p21Waf1/Cip1 promoter, we were able to define an Egr-1-binding site as a cis-acting element responsible for CPZ-inducible promoter activity. A chromatin immunoprecipitation assay revealed that Egr-1 is the transcription factor binding to the p21Waf1/Cip1 gene in response to CPZ treatment. The direct role of Egr-1 in regulation of CPZ-induced p21Waf1/Cip1 expression was further shown by exogenous expression of Egr-1. Stable knock-down of endogenous Egr-1 using siRNA targeted to Egr-1 mRNA attenuated CPZ-induced p21Waf1/Cip1 accumulation and G2/M cell cycle arrest. Thus, Egr-1 directly regulates transcription of the p21Waf1/Cip1 gene via an Egr-1 binding cis-acting response element. Our results agree with earlier reports regarding the role of Egr-1 in tamoxifen-induced up-regulation of p21Waf1/Cip1 in MDA-MB-361 breast cancer cells (Kim et al., 2007), in resveratrol-induced up-regulation of p21Waf1/Cip1 in K562 leukemia cells (Ragione et al., 2003), and in curcumin-induced p21Waf1/Cip1 expression in U-87MG human glioma cells (Choi et al., 2008a).

Egr-1 is a Cys2-His2 type zinc finger-containing transcription factor that regulates multiple tumor suppressors, including p21Waf1/Cip1, p53, TGFβ1, PTEN, fibronectin, Gadd45, and Sox18 (Virolle et al., 2001; Krones-Herzig et al., 2003; Thyss et al., 2005; Baron et al., 2006; Petrovic et al., 2010). Thus, Egr-1 appears to be a tumor suppressor. In contrast, Egr-1 plays an essential role in prostate tumor epithelial cells (Baron et al., 2003; Virolle et al., 2003). Previously, we reported that Trifluoperazine (TFP), a phenothiazine derivative, upregulates Egr-1 expression in cells (Shin et al., 2004), suggesting that Egr-1 expresses growth suppressor activity, at least in gliomas. Introduction of functional Egr-1 into human glioma primary cells results in growth arrest and eventual cell death (Calogero et al., 2004).

Germline TP53 mutations are frequently associated with glioma, particularly high-grade glioblastoma multiforme (Li et al., 1995), and loss of p53 function affects cellular response to radiation or chemotherapy. Adenovirus-based overexpression of Egr-1 almost completely abolishes glioma cell growth, regardless of the mutational status of the p53 gene (Calogero et al., 2004). Our results illustrate a potential use of the old antipsychotic agent CPZ as a chemopreventive and therapeutic supplement for human glioma. Furthermore, CPZ is widely available and can readily pass through the blood-brain barrier, making it an attractive candidate as an anticancer agent in central nervous system tumors.

In summary, our study provides further insight into the molecular mechanism of CPZ anticancer activity. CPZ induction of Egr-1 via the ERK and JNK MAP kinase pathways plays an important role in CPZ-induced p21Waf1/Cip1 expression independently of p53. CPZ appears to be an attractive adjuvant for various anticancer agents in p53-mutated human gliomas.


Cell culture and reagents

Rat C6 glioma cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT). Chlorpromazine (CPZ; Figure 1A) was purchased from Sigma-RBI (Natick, MA). Antibodies specific to phospho-ERK1/2 MAP kinase (Thr202/Tyr204), phospho-JNK1/2 (Thr183/Tyr185), and phosphor-p38 MAP kinase (Thr180/Tyr182) were obtained from Cell Signaling Technology (Beverly, MA). Antibodies for Egr-1, GAPDH, and ERK2 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The Dual-Glo™ Luciferase Assay System for firefly and Renilla luciferase activities was purchased from Promega (Madison, WI). pRL-null plasmids encoding Renilla luciferase were purchased from Promega (Madison, WI).

Cell proliferation assay

C6 cells seeded into 96-well plates (2 × 103) were treated with CPZ at increasing concentrations for different time periods (0, 12, 24, and 36 h). The proliferation rate was determined by using a Cell Counting Kit-8 (Dojindo Molecular Technologies, Gaithersburg, MD) with water-soluble tetrazolium salt, WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt], as a substrate.

Cell cycle analysis

Cellular DNA content was analyzed using flow cytometry as previously described (Choi et al., 2008a). Fluorescence was measured and analyzed using a FACSCalibur Flow Cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA).

Western blot analysis

Cells were lysed in 20 mM HEPES (pH 7.2), 1% Triton X-100, 10% glycerol, 150 mM NaCl, 10 µg/ml of leupeptin, and 1 mM phenylmethylsulphonyl fluoride. Western blotting was performed as described previously (Choi et al., 2008a).

Plasmid DNAs

Generation of the deletion construct of the p21Waf1/Cip1 promoter and mutagenesis to disrupt the Egr-1 binding site in the p21Waf1/Cip1 promoter are described elsewhere (Kim et al., 2007). The full-length and internal deletion constructs of the Egr-1 promoter expressing firefly luciferase were provided by Dr. H. Eibel (Department of Orthopedic Surgery, Research Laboratory University of Tubingen Medical Center, Tubingen, Germany) and are described elsewhere (Aicher et al., 1999).

Transient transfection and luciferase reporter assay

For promoter assay, C6 glioma cells were seeded into 12-well plates and transfected with 0.5 µg of Egr-1 or p21Waf1/Cip1 promoter constructs using LipofectAMINE 2000 reagents (Invitrogen Life Technologies, San Diego, CA) according to the manufacturer's instructions. To monitor the transfection efficiency, the pRL-null plasmid (50 ng) encoding Renilla luciferase (Promega, Madison, WI) was included in all samples. At 48-h post-transfection, cells were treated with CPZ. After 6 to 12 h, the firefly and Renilla luciferase activities were measured sequentially from a single sample using the Dual-Glo™ Luciferase Assay System. Luminescence was measured using a luminometer (Centro LB960; Berthold Tech, Bad Wildad, Germany) as previously described. (Kim et al., 2007)

Chromatin immunoprecipitation (ChIP) assay

C6 cells were either untreated or treated with 20 µM CPZ for 12 h. Protein-to-DNA cross-linking was performed by adding formaldehyde directly to the culture medium to obtain a final concentration of 1%. Preparation of crossed-linked chromatin and chromatin immunoprecipitation with anti-Egr-1 antibody was performed as described previously (Shin et al., 2009). For PCR amplification of promoter sequences of the p21Waf1/Cip1 gene, promoter-specific primers were used (5'-CTGGCCTGCTGGAACTC-3' as a forward primer, -170/-154, and 5'-CTCCACAAGGAACTGACTT-3' as a reverse primer, +42/+24).

Northern blot analysis

Total RNA (10 µg) for each sample was separated using electrophoresis on formaldehyde/agarose gel, and transferred to a Hybond N+ nylon membrane (Amersham Pharmacia Biotech.). Northern blotting was performed with a [γ-32P]dCTP-labeled Egr-1 cDNA probe, followed by hybridization with a GAPDH cDNA probe, as described previously (Choi et al., 2008a).

Expression of Egr-1 siRNA

Generation of the expression plasmid for short hairpin RNA (shRNA)-encoding small interfering RNA (siRNA) targeted to Egr-1 mRNA (pSilencer/siEgr1) is described elsewhere (Kim et al., 2007; Choi et al., 2008a). Stable C6 transfectants expressing Egr-1 siRNA are also described elsewhere (Choi et al., 2008a).

Statistical analysis

Each experiment was repeated at least three times. Data were plotted as the mean ± SD. Student's t-test was used for comparisons, and a value of P < 0.05 was considered significant.


This research was financially supported by a grant from the Korea Healthcare Technology R&D Project, the Ministry for Health, Welfare & Family Affairs (grant no. A084888), by the Korea Research Foundation Grant (KRF-2006-312-C00635), the Disease Network Research Program of the National Research Foundation of Korea (NRF), and the Ministry of Education, Science and Technology (grant no. 20090084181), Republic of Korea.


cyclin-dependent kinase inhibitor 1A
early growth response protein-1
serum response factor
ternary complex factor


1. Aicher WK, Sakamoto KM, Hack A, Eibel H. Analysis of functional elements in the human Egr-1 gene promoter. Rheumatol Int. 1999;18:207–214. [PubMed]
2. Baron V, Duss S, Rhim J, Mercola D. Antisense to the early growth response-1 gene (Egr-1) inhibits prostate tumor development in TRAMP mice. Ann NY Acad Sci. 2003;1002:197–216. [PubMed]
3. Baron V, Adamson ED, Calogero A, Ragona G, Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFβ1, PTEN, p53 and fibronectin: Egr1 is a potential target of gene therapy for prostate cancer. Cancer Gene Ther. 2006;13:115–124. [PMC free article] [PubMed]
4. Baus F, Gire V, Fisher D, Piette J, Dulić V. Permanent cell cycle exit in G2 phase after DNA damage in normal human fibroblasts. EMBO J. 2003;22:3992–4002. [PubMed]
5. Calogero A, Lombari V, De Gregorio G, Porcellini A, Ucci S, Arcella A, Caruso R, Gagliardi FM, Gulino A, Lanzetta G, Frati L, Mercola D, Ragona G. Inhibition of cell growth by EGR-1 in human primary cultures from malignant glioma. Cancer Cell Int. 2004;4:1–12. [PMC free article] [PubMed]
6. Chan TA, Hwang PM, Hermeking H, Kinzler KW, Vogelstein B. Cooperative effects of genes controlling the G2/M checkpoint. Genes Dev. 2000;14:1584–1588. [PubMed]
7. Charrier-Savournin FB, Château MT, Gire V, Sedivy J, Piette J, Dulic V. p21-Mediated nuclear retention of cyclin B1-Cdk1 in response to genotoxic stress. Mol Biol Cell. 2004;15:3965–3976. [PMC free article] [PubMed]
8. Choi BH, Kim CG, Bae YS, Lim Y, Lee YH, Shin SY. p21Waf1/Cip1 expression by curcumin in U-87MG human glioma cells: role of early growth response-1 expression. Cancer Res. 2008a;68:1369–1377. [PubMed]
9. Choi JH, Yang YR, Lee SK, Kim SH, Kim YH, Cha JY, Oh SW, Ha JR, Ryu SH, Suh PG. Potential Inhibition of PDK1/Akt Signaling by Phenothiazines Suppresses Cancer Cell Proliferation and Survival. Ann NY Acad Sci. 2008b;1138:393–403. [PubMed]
10. Derogatis LR, Morrow GR, Fetting J, Penman D, Piasetsky S, Schmale AM, Henrichs M, Carnicke CL., Jr The prevalence of psychiatric disorders among cancer patients. JAMA. 1983;249:751–757. [PubMed]
11. Eisenberg S, Giehl K, Henis YI, Ehrlich M. Differential interference of chlorpromazine with the membrane interactions of oncogenic K-Ras and its effects on cell growth. J Biol Chem. 2008;283:27279–27288. [PubMed]
12. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817–825. [PubMed]
13. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994;54:1169–1174. [PubMed]
14. Gartel AL, Tyner AL. Transcriptional regulation of the p21 (WAF1/CIP1) gene. Exp Cell Res. 1999;246:280–289. [PubMed]
15. Hamanaka R, Smith MR, O'Connor PM, Maloid S, Mihalic K, Spivak JL, Longo DL, Ferris DK. Polo-like kinase is a cell cycle-regulated kinase activated during mitosis. J Biol Chem. 1995;270:21086–21091. [PubMed]
16. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805–816. [PubMed]
17. Kim CG, Choi BH, Son SW, Yi SJ, Shin SY, Lee YH. Tamoxifen-induced activation of p21Waf1/Cip1 gene transcription is mediated by Early Growth Response-1 protein through the JNK and p38 MAP kinase/Elk-1 cascades in MDA-MB-361 breast carcinoma cells. Cell Signal. 2007;19:1290–1300. [PubMed]
18. Krones-Herzig A, Adamson E, Mercola D. Early growth response 1 protein, an upstream gatekeeper of the p53 tumor suppressor, controls replicative senescence. Proc Natl Acad Sci USA. 2003;100:3233–3238. [PubMed]
19. Lee MS, Johansen L, Zhang Y, Wilson A, Keegan M, Avery W, Elliott P, Borisy AA, Keith CT. The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action. Cancer Res. 2007;67:11359–11367. [PubMed]
20. Li YJ, Sanson M, Hoang-Xuan K, Delattre JY, Poisson M, Thomas G, Hamelin R. Incidence of germ-line p53 mutations in patients with gliomas. Int J Cancer. 1995;64:383–387. [PubMed]
21. Nordenberg J, Fenig E, Landau M, Weizman R, Weizman A. Effects of psychotropic drugs on cell proliferation and differentiation. Biochem Pharmacol. 1999;58:1229–1236. [PubMed]
22. Noyes R., Jr Treatment of cancer pain. Psychosom Med. 1981;43:57–70. [PubMed]
23. Petrovic I, Kovacevic-Grujicic N, Stevanovic M. Early growth response protein 1 acts as an activator of SOX18 promoter. Exp Mol Med. 2010;42:132–142. [PMC free article] [PubMed]
24. Ragione FD, Cucciolla V, Criniti V, Indaco S, Borriello A, Zappia V. p21Cip1 Gene Expression Is Modulated by Egr1. J Biol Chem. 2003;278:23360–23368. [PubMed]
25. Schratt G, Weinhold B, Lundberg AS, Schuck S, Berger J, Schwarz H, Weinberg RA, Rüther U, Nordheim A. Serum response factor is required for immediate-early gene activation yet is dispensable for proliferation of embryonic stem cells. Mol Cell Biol. 2001;21:2933–2943. [PMC free article] [PubMed]
26. Shin SY, Kim SY, Kim JH, Min DS, Ko J, Kang UG, Kim YS, Kwon TK, Han MY, Kim YH, Lee YH. Induction of early growth response-1 gene expression by calmodulin antagonist trifluoperazine through the activation of Elk-1 in human fibrosarcoma HT1080 cells. J Biol Chem. 2001;276:7797–7805. [PubMed]
27. Shin SY, Kim CG, Hong DD, Kim JH, Lee YH. Implication of Egr-1 in trifluoperazine-induced growth inhibition in human U 87 MG glioma cells. Exp Mol Med. 2004;36:380–386. [PubMed]
28. Shin SY, Song H, Kim CG, Choi YK, Lee KS, Lee SJ, Lee HJ, Lim Y, Lee YH. Egr-1 Is Necessary for Fibroblast Growth Factor-2-induced Transcriptional Activation of the Glial Cell Line-derived Neurotrophic Factor in Murine Astrocytes. J Biol Chem. 2009;284:30583–30593. [PMC free article] [PubMed]
29. Snyder SH, Banerjee SP, Yamamura HI, Greenberg D. Drugs, Neurotransmitters, and Schizophrenia. Science. 1974;184:1243–1253. [PubMed]
30. Thyss R, Virolle V, Imbert V, Peyron JF, Aberdam D, Virolle T. NF-κB/Egr-1/Gadd45 are sequentially activated upon UVB irradiation to mediate epidermal cell death. EMBO J. 2005;24:128–137. [PubMed]
31. Treisman R. Ternary complex factors: growth factor regulated transcriptional activators. Curr Opin Genet Dev. 1994;4:96–101. [PubMed]
32. Virolle T, Adamson ED, Baron V, Birle D, Mercola D, Mustelin T, de Belle I. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol. 2001;3:1124–1128. [PubMed]
33. Virolle T, Krones-Herzig A, Baron V, De Gregorio G, Adamson ED, Mercola D. Egr1 promotes growth and survival of prostate cancer cells. Identification of novel Egr1 target genes. J Biol Chem. 2003;278:11802–11810. [PubMed]
34. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature. 1996;381:713–716. [PubMed]
35. Watson DK, Robinson L, Hodge DR, Kola I, Papas TS, Seth A. FLI1 and EWS-FLI1 function as ternary complex factors and ELK1 and SAP1a function as ternary and quaternary complex factors on the Egr1 promoter serum response elements. Oncogene. 1997;14:213–221. [PubMed]
36. Yang SH, Whitmarsh AJ, Davis RJ, Sharrocks AD. Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1. EMBO J. 1998;17:1740–1749. [PubMed]
37. Yang SH, Sharrocks AD. Convergence of the SUMO and MAP kinase pathways on the ETS-domain transcription factor Elk-1. Biochem Soc Symp. 2006;73:121–129. [PubMed]
38. Zarnowska ED, Mozrzymas JW. Differential effects of chlorpromazine on ionotropic glutamate receptors in cultured rat hippocampal neurons. Neurosci Lett. 2001;305:53–56. [PubMed]

Articles from Experimental & Molecular Medicine are provided here courtesy of Korean Society for Biochemistry and Molecular Biology